-
-
-
-
-
-
-
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab
-
-
-
-
-
-
-
Ivonescimab shows survival benefit in lung cancer study
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT) After Management Meet
-
-
-
-
-
-
-
Summit presents lung cancer trial data at ESMO 2025
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Clear Street Starts Summit Therapeutics plc (SMMT) at Buy
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

